TY - JOUR
T1 - High-risk prescription opioid use among people living with HIV
AU - HIV Research Network
AU - Canan, Chelsea E.
AU - Chander, Geetanjali
AU - Monroe, Anne K.
AU - Gebo, Kelly A.
AU - Moore, Richard D.
AU - Agwu, Allison L.
AU - Alexander, G. Caleb
AU - Lau, Bryan
AU - Edelstein, Howard
AU - Rutstein, Richard
AU - Baranoski, Amy
AU - Allen, Sara
AU - Boswell, Stephen
AU - Beil, Robert
AU - Felsen, Uriel
AU - Aberg, Judith
AU - Urbina, Antonio
AU - Korthuis, P. Todd
AU - Nijhawan, Ank
AU - Akbar, Muhammad
AU - Gaur, Aditya
AU - Somboonwit, Charurut
AU - Valenti, William
AU - Mathews, W. Christopher
AU - Hellinger, Fred
AU - Fleishman, John
AU - Fraser, Irene
AU - Mills, Robert
AU - Malitz, Faye
AU - Keruly, Jeanne
AU - Voss, Cindy
AU - Collins, Charles
AU - Diaz-Reyes, Rebeca
N1 - Funding Information:
From the *Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; †Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD; and ‡Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD C.E.C. received grant T32-AI102623 from the National Institutes of Health. G.C., R.D.M., and HIVRN received grant U01-DA036935 from the National Institutes of Health. R.D.M., B.L., and HIVRN received grant P30-AI094189 from the Johns Hopkins Center for AIDS Research Clinical Core and Biostatistics and Methodology Core, a National Institutes of Health funded program. A.K.M. received grant K23-MH105284 from the National Institutes of Health. HIVRN received grant HHSA290201100007C from the Agency for Healthcare Research and Quality, grant HHSH250201600009C from the Health Resources and Services Administration, and P30-AI036214 from the Clinical Investiga-tion and Biostatistics Core of the UC San Diego Center for AIDS Research, a National Institutes of Health funded program.
Publisher Copyright:
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Background: Prescription opioid use is greater among people living with HIV (PLWH), yet little is known about the prevalence of specific types of high-risk use among these individuals. Setting: We analyzed clinical and demographic data from the HIV Research Network and prescribing data from Medicaid for noncancer patients seeking HIV treatment at 4 urban clinics between 2006 and 2010. Methods: HIV Research Network patients were included in the analytic sample if they received at least one incident opioid prescription. We examined 4 measures of high-risk opioid use: (1) high daily dosage; (2) early refills; (3) overlapping prescriptions; and (4) multiple prescribers. Results: Of 4605 eligible PLWH, 1814 (39.4%) received at least one incident opioid prescription during follow-up. The sample was 61% men and 62% African American with a median age of 44.5 years. High-risk opioid use occurred among 30% of incident opioid users (high daily dosage: 7.9%; early refills: 15.9%; overlapping prescriptions: 16.4%; and multiple prescribers: 19.7%). About half of the cumulative incidence of high-risk use occurred within 1 year of receiving an opioid prescription. After adjusting for study site, high-risk opioid use was greater among patients with injection drug use as an HIV risk factor [adjusted hazard ratio (aHR) = 1.39, 95% confidence interval: 1.11 to 1.74], non-Hispanic whites [aHR = 1.61, (1.21 to 2.14)], patients age 35–45 [aHR = 1.94, (1.33 to 2.80)] and 45–55 [aHR = 1.84, (1.27 to 2.67)], and patients with a diagnosis of chronic pain [aHR = 1.32, (1.03 to 1.70)]. Conclusions: A large proportion of PLWH received opioid prescriptions, and among these opioid recipients, high-risk opioid use was common. High-risk use patterns often occurred within the first year, suggesting this is a critical time for intervention.
AB - Background: Prescription opioid use is greater among people living with HIV (PLWH), yet little is known about the prevalence of specific types of high-risk use among these individuals. Setting: We analyzed clinical and demographic data from the HIV Research Network and prescribing data from Medicaid for noncancer patients seeking HIV treatment at 4 urban clinics between 2006 and 2010. Methods: HIV Research Network patients were included in the analytic sample if they received at least one incident opioid prescription. We examined 4 measures of high-risk opioid use: (1) high daily dosage; (2) early refills; (3) overlapping prescriptions; and (4) multiple prescribers. Results: Of 4605 eligible PLWH, 1814 (39.4%) received at least one incident opioid prescription during follow-up. The sample was 61% men and 62% African American with a median age of 44.5 years. High-risk opioid use occurred among 30% of incident opioid users (high daily dosage: 7.9%; early refills: 15.9%; overlapping prescriptions: 16.4%; and multiple prescribers: 19.7%). About half of the cumulative incidence of high-risk use occurred within 1 year of receiving an opioid prescription. After adjusting for study site, high-risk opioid use was greater among patients with injection drug use as an HIV risk factor [adjusted hazard ratio (aHR) = 1.39, 95% confidence interval: 1.11 to 1.74], non-Hispanic whites [aHR = 1.61, (1.21 to 2.14)], patients age 35–45 [aHR = 1.94, (1.33 to 2.80)] and 45–55 [aHR = 1.84, (1.27 to 2.67)], and patients with a diagnosis of chronic pain [aHR = 1.32, (1.03 to 1.70)]. Conclusions: A large proportion of PLWH received opioid prescriptions, and among these opioid recipients, high-risk opioid use was common. High-risk use patterns often occurred within the first year, suggesting this is a critical time for intervention.
KW - HIV
KW - Medicaid
KW - Opioid misuse
KW - Prescription opioids
UR - http://www.scopus.com/inward/record.url?scp=85063287052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063287052&partnerID=8YFLogxK
U2 - 10.1097/QAI.0000000000001690
DO - 10.1097/QAI.0000000000001690
M3 - Article
C2 - 29601405
AN - SCOPUS:85063287052
SN - 1525-4135
VL - 78
SP - 283
EP - 290
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 3
ER -